Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia
© Cui et al.; licensee BioMed Central Ltd. 2012
Received: 27 January 2012
Accepted: 15 May 2012
Published: 15 May 2012
Cerebral ischemia has been shown to induce activation of matrix metalloproteinases (MMPs), particularly MMP-9, which is associated with impairment of the neurovasculature, resulting in blood–brain barrier breakdown, hemorrhage and neurodegeneration. We previously reported that the thiirane inhibitor SB-3CT, which is selective for gelatinases (MMP-2 and −9), could antagonize neuronal apoptosis after transient focal cerebral ischemia.
Here, we used a fibrin-rich clot to occlude the middle cerebral artery (MCA) and assessed the effects of SB-3CT on the neurovasculature. Results show that neurobehavioral deficits and infarct volumes induced by embolic ischemia are comparable to those induced by the filament-occluded transient MCA model. Confocal microscopy indicated embolus-blocked brain microvasculature and neuronal cell death. Post-ischemic SB-3CT treatment attenuated infarct volume, ameliorated neurobehavioral outcomes, and antagonized the increases in levels of proform and activated MMP-9. Embolic ischemia caused degradation of the neurovascular matrix component laminin and tight-junction protein ZO-1, contraction of pericytes, and loss of lectin-positive brain microvessels. Despite the presence of the embolus, SB-3CT mitigated these outcomes and reduced hemorrhagic volumes. Interestingly, SB-3CT treatment for seven days protected against neuronal laminin degradation and protected neurons from ischemic cell death.
These results demonstrate considerable promise for the thiirane class of selective gelatinase inhibitors as potential therapeutic agents in stroke therapy.
Stroke is a devastating cerebrovascular disease with an estimated 800,000 cases each year and mortality data from 2006 indicated that stroke accounted for approximately 1 out of every 18 deaths in the U.S. . Acute ischemic stroke is the most common form of stroke and is majorly caused by thrombosis or embolism in the cerebral arteries. Blockage of blood flow (ischemia) results in oxygen deprivation, glucose deficiency in the affected region, and infarction in the brain. Cerebral ischemia initiates cascades of pathological events, including vasogenic edema, disruption of the blood–brain barrier (BBB), intracerebral hemorrhage (ICH), astroglial activation, and neuronal death [2, 3]. Although the molecular mechanisms underlying these outcomes have not yet been fully addressed, there is considerable evidence supporting the important role of matrix metalloproteinases (MMPs) in mediating ischemia-induced neurovasculature impairment. Increased expression and activation of MMPs, and gelatinases in particular, are likely to play critical roles in excitotoxicity-induced disruption of cell-matrix homeostasis and neuronal cell death [4, 5]. MMPs also play a role in thrombolysis-mediated BBB leakage and edema, resulting in ICH. In clinical settings, MMP-mediated neurotoxicity and hemorrhagic transformation during the acute phase of cerebral ischemia are frequently complicated upon treatment with tissue plasminogen activator (tPA) . In addition, gelatinases function in neurovascular remodeling and microvascular recanalization [2, 7, 8].
MMPs comprise a family of zinc-containing endoproteases that degrade components of the extracellular matrix (ECM) and tight-junctions in the brain. MMPs are also needed for modulating interactions between cells during development and tissue remodeling [5, 7]. Reportedly, unregulated MMP activity contributes to neurological disorders, including stroke and other inflammatory responses. MMP-9 activity, in particular, is significantly elevated in humans after stroke [9–11]. High plasma MMP-9 concentrations in the acute phase of a cerebral infarct are considered as independent predictors of hemorrhagic transformation in all stroke subtypes . We and others have shown that aberrant MMP-9 proteolytic activity is associated with an increase in BBB permeability, which results in brain edema and hemorrhage, and contributes directly to neuronal injury, apoptosis and brain damage after acute cerebral ischemia [13–16]. Moreover, cerebral infarct size is reduced in mice deficient in MMP-9, or after treatment with MMP inhibitors .
Among the different cell types in the neurovasculature, pericytes are known to play a role in safeguarding the brain against injury, and control key neurovascular functions and neuronal phenotype in the adult and aging brain [18–20]. Loss of pericytes, associated with accumulation of neurotoxic and vasculotoxic macromolecules in the brain, could reduce brain microcirculation, diminish brain capillary perfusion, and disrupt the BBB, leading to vascular damage. Analysis of pericyte-deficient mice (e.g., with Pdgfb mutants) reveals that pericyte deficiency leads to increased permeability of the BBB, which probably occurs by facilitating endothelial transcytosis . Although MMP-9 inhibition or knockout can attenuate proteolysis of BBB [13, 17], more recent studies suggest its possible role in neurovascular regeneration, especially in the delayed phase of cerebral ischemia . Thus, successful anti-stroke therapies require selective inhibition of aberrant activity without altering the physiological function of MMPs, such as their roles in axonal growth, synaptic plasticity, and vascularization in the central nervous system [22–26].
Pathologically activated therapy (PAT) is a novel neuroprotective strategy based on the principle that drugs are activated during the pathological state of the target, while sparing normal tissue function . One PAT strategy is the target-induced activation of MMP inhibitors. Specifically, (4-phenoxyphenylsulfonyl)methylthiirane (referred to as SB-3CT) is the first mechanism-based MMP inhibitor selective for gelatinases . Active gelatinases bind to SB-3CT and catalyze the opening of the thiirane ring in the molecule. The resultant species generated within the active site of the enzyme affords tight binding between the inhibitor and the enzyme. That is to say, the activity of the enzyme generates the potent inhibitory species within the active site. This mechanism-based inhibition confers a PAT strategy to abrogate the deleterious activity of gelatinases, making this class of inhibitors potentially suitable for more prolonged treatment, because of the selectivity that it affords. We first reported that SB-3CT prevents proteolysis of the ECM basement membrane laminin and rescues neurons from focal cerebral ischemia . Most importantly, significant therapeutic benefit can be observed for up to 6 hours after initial injury. Recent studies show that SB-3CT abolishes oxygen-glucose deprivation-induced reduction of the tight junction protein occludin as well as decreases Evans blue extravasation and apoptotic cell death after spinal cord injury, subarachnoid hemorrhage [30–32], and cardiopulmonary resuscitation-induced BBB disruption . These results are consistent with the notion that inhibiting pathological gelatinolytic activity can maintain the brain neurovascular integrity and protect it from ischemia or other neurovascular insults.
In the present study, we use a fibrin-rich blood clot to induce middle cerebral artery (MCA) occlusion in mice. This embolus-induced focal cerebral ischemia model is more physiologically relevant to thromboembolic stroke in humans. We demonstrate the protective effects of SB-3CT on the neurovascular unit, and document that SB-3CT can manifest inhibitory activity even in the presence of an embolus blocking the MCA and its branches. We disclose that repeated-dose administration of SB-3CT over seven days in the embolus-induced “permanent” focal cerebral ischemia model also protects the brain from neurovascular impairment with no apparent cytotoxicity.
Embolus-induced focal cerebral ischemia in mice
Next, we examined the embolic blockage of the MCA-supplied microvasculature by intravenous infusion of a fluorescence-labeled macromolecule. Confocal microscopy with fluorescein isothiocyanate (FITC)-dextran (2,000 kDa) revealed the embolus-blocked microvasculature as marked by dashed white lines in a representative serial brain section, indicating the presence of infarct (Figure 1D). As expected, the contralateral side (left intracranial segment) of the internal carotid artery was unaffected. Examination of the embolic region by cresyl violet staining revealed extensive cell death with small-condensed nuclei in the ischemic hemisphere (data not shown).
SB-3CT reduces infarct volume and ameliorates behavioral functions after embolic cerebral ischemia
SB-3CT inhibits MMP-9 activity in the embolus-induced ischemic brain
SB-3CT protects laminin-positive pericytes from embolus-induced ischemic lesion by relieving them from gelatinase-mediated lumen contraction after embolic MCA occlusion
By double immunostaining for laminin and α-SMA, we compared mice treated with SB-3CT to vehicle-treated animals in both the ischemic cortex and the contralateral region. This experiment examined the effects of SB-3CT on gelatinase-associated laminin degradation and changes in the lumen diameter by pericytes. Pericytes were seen as annular cells surrounding the vascular lumen in the non-ischemic cortex (Figure 5A), with average lumen diameters of 5 ~ 10 μm. We further observed significant decreases in laminin-positive pericytes (Figures 5B and 5C) and pericyte-encircled lumen diameters in the ischemic penumbral cortex compared to the contralateral regions (Figure 5D). A higher magnification of the α-SMA-positive pericytes showed pericyte lumen contraction after embolus-induced cerebral ischemia (Additional file 2: Figure S2), suggesting that embolic ischemia caused loss of α-SMA-positive pericytes and increased pericyte lumen contraction. In the ischemic penumbral cortex, SB-3CT treatment protected laminin-positive pericytes by significantly increasing their numbers and the average pericyte lumen diameter (Figures 5C-5D). These results indicate that SB-3CT can reduce the loss of laminin-positive pericytes, relieve them from ischemic contraction and restore microvascular patency, thus protecting against neurovascular impairment in embolus-induced focal ischemia in mice.
SB-3CT attenuates gelatinase-mediated impairment of the neurovascular unit and reduces intracerebral hemorrhage in ischemic mice
Next, we investigated the effects of SB-3CT on the integrity of neurovasculature by examining microvascular endothelial cells using the specific endothelial marker glycoprotein Lycopersicon esculentum (tomato) lectin-FITC and the BBB tight-junction protein ZO-1. Fluorescence staining revealed that microvascular lectin-FITC immunoreactivity colocalized with the well-documented antibody marker CD31 for endothelial cells (Additional file 3: Figure S3). We observed loss of microvascular endothelial cells in the embolus-induced ischemic cortex (Figure 6C). In contrast, SB-3CT protected against endothelial deformation and antagonized the loss of lectin-positive brain capillary endothelial cells. We also observed gelatinase-mediated degradation of the tight-junction protein ZO-1 and fragmentation of the ECM laminin in the ischemic cortex (Additional file 4: Figure S4). These findings were similar to those previously reported by us and others [13, 15, 17, 29, 38]. Taken together, these data indicate that an impaired neurovasculature leads to secondary micro-hemorrhages and that SB-3CT protects against gelatinase-mediated neurovasculature impairment in embolic ischemia.
Repeated-dose SB-3CT treatment attenuates degradation of neuronal laminin, protects neurons from ischemia and improves neurobehavioral outcomes after embolic MCA occlusion
In the present study, we investigated the selective gelatinase inhibitor SB-3CT in a mouse model of embolus-induced “permanent” focal cerebral ischemia. We demonstrated the following key findings: (1) the autologous blood clot embolus model is a reliable, physiologically induced focal ischemia model, highly relevant to thromboembolic stroke in humans; (2) the selective gelatinase inhibitor SB-3CT can inhibit MMP-9 activity in vivo, attenuate ECM basement membrane laminin degradation, prevent pericyte lumen from contraction, and protect pericytes and endothelial cells, thus playing an important role in preserving neurovascular integrity and reducing hemorrhage; and (3) repeated-dose SB-3CT treatment can counteract degradation of neuronal laminin, protect neurons from ischemic cell death, and ameliorate neurobehavioral outcomes after embolic MCA occlusion in mice.
The rodent embolus model has distinct advantages in testing anti-thrombolytic and neuroprotectant agents for cerebral ischemia and is recommended by the Stroke Therapy Academic Industry Roundtable (STAIR) . In our embolic model, the MCA supporting the brain region blocked by the embolus shows insufficient perfusion compared to the contralateral hemisphere. This model mimics the pathological conditions of an autologous clot-induced MCA occlusion. Initially, one of our goals was to test the reliability of the embolus model in comparison with the widely used filament model [29, 34–36]. We also aimed to extend previous studies with the selective gelatinase inhibitor SB-3CT in the embolus model in mice, and further evaluate the suitability of the selective gelatinase inhibitor after two doses on day 1 or repeated-dose administration for 7 days. Results from this study indicate that the embolus model can be used to test thrombolytic or neuroprotective agents.
In the developing and adult brains, MMP proteolytic activity is known to play roles in modulating diverse physiological functions in the central nervous system, such as ECM remodeling, myelin turnover, axon outgrowth, angiogenesis, long-term potentiation, and synaptic plasticity in memory and spatial learning [5, 7, 25, 26]. However, these enzymes also play important roles in mediating pathological processes, especially after stroke or traumatic injuries [5, 7]. Elevated MMP-9 activity is correlated with BBB disruption, brain edema, hemorrhagic transformation, and neuronal apoptosis [2, 4, 12, 13]. There is evidence indicating that specific inhibition of MMP activity during stroke onset or immediately following brain injury likely improves neurological outcomes. Lo and colleagues reported that minocycline, a broad-spectrum MMP inhibitor, could reduce neuronal cell death after ischemia and extend the thrombolytic time window . Moreover, MMP-9 knockout can stabilize the BBB by preventing degradation of the tight-junction protein ZO-1 . During ischemic stroke, MMP-9 inhibition also mitigates BBB disruption and reperfusion injury experimentally induced by the thrombolytic agent tPA, a therapeutic agent that can itself increase the risk of bleeding [6, 14]. A recent clinical trial indicated that minocycline can lower plasma MMP-9 levels, even at 72 hours after stroke, and improve neurological outcomes in acute ischemic stroke patients treated with tPA . In the present study, using the embolus-induced ischemia model, treatment with SB-3CT revealed an unexpected finding as compared to the control group. During ischemia, expression of inactive proMMP-9 increased significantly, a small portion of which was processed to active MMP-9, which manifests the pathological consequences of ischemia. When ischemic animals were treated with SB-3CT, we observed a general down regulation of proMMP-9 expression. This could be the consequence of a feedback process whereby active MMP-9 interacting with SB-3CT via its thiolate acts on an unknown downstream target to modulate the MMP-9 expression by transcription factors such as NF-kappa B and AP-1 .
MMPs have been implicated in beneficial roles in recovery following stroke. Shortly after ischemic insult, a cascade of events is initiated in attempt to repair the damage, a process similar to that found in wound healing [5, 7]. Following injury, blood vessels are dependent on the plasminogen-activator system and on MMPs for their regeneration . For example, Lo and colleagues showed that delayed inhibition of MMPs by broad-spectrum inhibitors is detrimental during the ischemic recovery stage seven days after cerebral ischemia, hindering brain repair in mice, and attenuating neurovascular regeneration in the penumbra . Perhaps, a suitable balanced level of MMP-9 activity is important for vascular remodeling after spinal cord injury . Therefore, extended inhibition of MMPs, especially through the use of broad-spectrum inhibitors, might prove deleterious [2, 5].
In the present study, we observed that the mNSS scores of both motor and sensory functions after two-doses of SB-3CT on day 1 are significantly lower, compared to the vehicle-treated group (Figure 3C). Moreover, repeated-dose administration of SB-3CT for seven days appears to offer beneficial effects after embolic ischemic injury, as demonstrated by its ability to attenuate degradation of neuronal laminin, protect neurons from ischemia shown on cresyl violet stained brain sections and ameliorate neurobehavioral outcomes (Figure 7). These data are in line with the decrease in infarct volume and the ability of SB-3CT to protect the brain from ischemic damage. Measurement of the sensory functions showed significant improvement at the end of the seven-day SB-3CT treatment, but no further change in motor function (Fig. 7C). However, we observed that mice in the vehicle-treated group had significantly improved motor functions by seven days after ischemia, as indicated by a diminution in their motor function mNSS from a score of 5 at day 1 to a score of 2 at day 7. It has been shown that rodents are able to recover gradually in motor function after ischemic insult despite persistence of the infarct area [43, 44]. These observations for the improvement in motor function might be due to compensatory effects of the endogenous neurogenic response and/or subsequent retrieval of interhemispheric functional connectivity within the sensorimotor system in rodents. Nevertheless, repeated-dose administration of SB-3CT for seven days offered beneficial effects, such as protecting neurons and ameliorating neurobehavioral functions in stroke outcomes relative to vehicle-treated mice. On the other hand, delayed treatment with the broad-spectrum MMP inhibitors FN-439 (day 3 or 7) and BB-94 (day 7) significantly worsened infarct volumes . Since these broad-spectrum MMP inhibitors are peptidomimetics and they were administered intraventricularly , they are unlikely to cross the BBB. In contrast, SB-3CT crosses the BBB in healthy animals (unpublished data). These data suggest the benefit of selective gelatinase inhibitors over broad-spectrum MMP inhibitors .
Using the embolic model for “permanent” MCA occlusion in mice, we documented the protective effects of SB-3CT on the neurovascular unit. Since SB-3CT is a small molecule that distributes to the brain, it enters the brain via the unaffected vasculature, and diffuses to the infarct regions to manifest its inhibitory activity. In this study, we demonstrated the protective effects of SB-3CT despite the fact that the embolus remained intact in the brain during the course of treatment. As such, this inhibitor is considered a PAT agent. The basis of the selectivity of SB-3CT is the ability of gelatinases to catalyze a requisite thiirane-ring opening of the SB-3CT structure . The thiolate, formed only within the active site of gelatinase, is capable of coordinating with the active-site zinc ion, and precipitates potent “slow-binding” inhibition, a hallmark of this class of inhibitors. Inhibition inherent to this class of compounds suppresses pathological activity of the target gelatinase, which is activated during the diseased state . Under this condition, the inhibitory effect of SB-3CT is limited to gelatinases. In addition to stroke, this mechanism-based, selective gelatinase inhibitor can exhibit promising efficacy on other diseases. For example, recent studies demonstrated that SB-3CT attenuates BBB damage by decreasing oxygen-glucose deprivation-induced occludin degradation in early ischemic stroke, protects against oxidative stress-mediated apoptosis after spinal cord injury, and increases proliferation of NG2 progenitor cells after spinal cord injury [30, 32, 46]. Another study showed that SB-3CT could prevent laminin degradation and ameliorate neuronal death in a rat model of subarachnoid hemorrhage . Taken together, these studies along with the recent findings of SB-3CT on neurovasculature [8, 20], indicate that SB-3CT has promise in the treatment of gelatinase-mediated diseases. The inhibitor also exhibits significant efficacy in maintaining brain neurovascular integrity and protective effects on neuroinflammation against degradation of ECM components, pericyte lumen contraction, BBB disruption, neuronal apoptosis, and hemorrhagic transformation in brain and spinal cord injuries.
Brain function and neuronal viability are dictated by the adequate delivery of oxygen and glucose through cerebral microvessels. Because of their small diameter and relatively low flow velocity, microvessels are prone to occlusion by thromboembolism. Substantial evidence indicates that pathological MMP-9 activity after cerebral ischemia degrades components of the ECM and tight-junctions, thus contributing to microvessel and BBB leakage [13, 17]. We previously showed that MMP-9 activation is essential for degradation of laminin after focal cerebral ischemia . Pericytes are known to play a role in modulating capillary diameter by constricting the vascular wall, a process that can obstruct capillary blood flow during ischemia in the adult brain . In this study, we observed a significant decrease in laminin-positive pericytes, and an increase in pericyte lumen contraction in the ischemic cortex (Figure 5). Because oxidative and nitrosative stress might promote capillary constriction after ischemia, and S-nitrosylation contributes to MMP-9 activation after stroke , it is reasonable to consider pericytes as critical targets for MMP-9 proteolytic activity after cerebral ischemia. The ability of SB-3CT to protect laminin-positive pericytes, and inhibit lumen contraction after embolic MCA occlusion is critical for its efficacy in restoring microvascular patency and protecting against neurovascular impairment. Moreover, the ability of SB-3CT to attenuate gelatinase-mediated damage of endothelial cells and BBB tight-junction ZO-1 and to protect against endothelial deformation is important in its ability to decrease ICH in ischemic mice.
In summary, we used an embolic cerebral ischemia mouse model to evaluate SB-3CT, a mechanism-based selective and potent gelatinase inhibitor. We demonstrated MMP-9 activation and neurovasculature impairment in stroke, and showed the ability of SB-3CT to inhibit MMP-9 activity in vivo, which resulted in maintenance of laminin, antagonism of pericyte contraction and loss, and preservation of laminin-positive pericytes and endothelial cells. Thus, SB-3CT rescued neurons from apoptosis and prevented ICH. Selective targeting of MMP-9 antagonizes disruption of the neurovascular unit and protects against brain damage and vessel constriction. Taken together, these results strongly indicate that thiirane class of gelatinase selective inhibitors holds great promise as therapeutic agents for the treatment of stroke.
Animal models of focal cerebral ischemia in mice
Adult male C57Bl/6 J mice (The Jackson Laboratory, Bar Harbor, Maine, USA), 6–9 weeks of age and weighing 20–28 g were housed in a 12 hours light/dark cycle and permitted food and water intake ad libitum . All groups in the animal experiments were performed in a randomized, blinded manner at the University of Missouri according to an institutionally approved protocol in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice were anesthetized with isoflurane (1–1.5%) masked with a gas mixture of 30% oxygen and 70% nitrogen. Rectal temperatures were maintained at 37 ± 0.5°C with animals placed on a thermostat-controlled heating pad.
Two mouse models of focal cerebral ischemia were used: an embolic model using autologous clots to occlude the MCA and a filament model described previously [29, 34–36]. For the latter, C57BL/6 J mice were subjected to right MCA occlusion by insertion of a 6–0 monofilament to block the MCA for 2 hours, and followed by filament withdrawal for arterial reperfusion. For the embolic model, homologous blood clots were prepared by a modification of earlier methods . Briefly, femoral arterial blood from a donor mouse was withdrawn into a 3-foot long PE-50 polyethylene tubing, incubated at 37°C for 2 hours, and cooled at 4°C overnight to allow the formation of fibrin-rich blood clots. Blood clots were then washed with sterile phosphate buffered saline (PBS) in a 2-foot long PE-10 tubing for 6 ~ 8 rounds. After ejection from the PE-10 tubing, clots were cut into 10-mm long (0.02 μl) pieces. A single piece autologous clot was inserted via a PE-10 catheter with a modified tip of ~0.20 mm outer diameter from the external cerebral artery into the internal cerebral artery lumen to occlude the MCA. The catheter was immediately removed after injection. Both models required approximately 15–20 min (no longer than 20 min) from the start of anesthesia to completion of the surgery; animals were not included in the subsequent study if the surgery took over 20 min. A total of 94 mice were used in the subsequent study.
SB-3CT, a discovery from the Mobashery laboratory, was synthesized for this study by reported methodology . Mice were divided into four groups: vehicle-treated group and SB-3CT-treated one with treatment for either one day or seven days after embolic MCA occlusion. SB-3CT (12.5 mg/mL) was freshly dissolved in 25% DMSO/65% PEG-200/10% water and filtered through an Acrodisc syringe filter with a 0.2 μm, 13-mm diameter sterile hydrophobic PTFE membrane (VWR, West Chester, PA). Mice were ip injected with 2 μL/gram body weight of this solution (equivalent to 25 mg/kg) 2 hours after embolic ischemia, followed by an additional dose at 4 hours. In repeated-dose treatment conditions, the same dose of SB-3CT was ip administered 2 and 4 hours after embolic ischemia, followed by once daily from post-ischemia day 1 to 6. Earlier work indicated that ip administration of SB-3CT does not alter mean arterial blood pressure, pH, PCO2, and PO2.
Monitoring of regional cerebral blood flow by laser doppler flowmetry
A laser Doppler probe (Moor Instruments, Devon, UK) was used to continuously monitor rCBF to ensure MCA occlusion. rCBF was expressed as a percentage of pre-ischemic baseline values. A total of 86 mice were used for embolic ischemia and approximately 80% of the mice showing sustained MCA blockage of less than 25% of pre-ischemic rCBF baselines were included in the subsequent study.
Analysis of neurobehavioral deficits was conducted by individuals blinded to coded treatment groups. Animals underwent neurological evaluation using the 14-point mNSS on days 1 and 7 after embolic MCA occlusion. Neurobehavioral outcomes of the mNSS include a composite of motor, sensory and reflex tests, as described . In scoring injury, one score point was awarded for the inability to perform a test or for the lack of a tested reflex; thus, the higher the score, the more severe the injury. Neurological function was graded on a scale of 0–14 (0 = normal, 14 = maximal deficit).
Measurement of infarct volume
After neurological assessment, mice were sacrificed with an overdose of isoflurane and transcardially perfused with PBS to remove intravascular blood and brains were rapidly harvested. Coronal brain sections (1 mm thick) were stained with 2,3,5-triphenyltetrazolium chloride (TTC, Sigma, St. Louis, MO). Infarct volumes were quantified using the ImageJ analysis software, where TTC lesion areas from each slice were integrated to yield total ischemic lesion volumes. To minimize errors associated with edema during tissue processing for histological analysis, infarct volume is presented as a percentage of infarct volume relative to the volume measured in the contralateral hemisphere (indirect volume calculation) [21, 29, 35].
Zymographic assays of gelatinolytic activity
Gelatin zymography was carried out as described . Briefly, gelatinases were extracted in Tris-buffered saline, pH 7.6, followed by affinity precipitation with gelatin-Sepharose 4B. Bound material was released from the beads using 10% DMSO; the samples were analyzed by electrophoresis in a 10% gelatin zymogram gel under non-reductive conditions, followed by incubation overnight at 37°C in Tris buffer, pH 8, with 5 mM CaCl2. As a control, EDTA was added to other samples to inhibit all MMP activities. Gels were stained with Coomassie blue and digitized for densitometry analysis.
Histological staining and assessment of brain damage
At days 1 or 7 after embolic ischemia, mice were sacrificed and brains were processed for histochemical staining using the stereology technique as described [36, 39]. Briefly, brains were dissected and submerged in 4% paraformaldehyde overnight at 4°C. Coronal sections were serially cut through the entire brain at 40 μm intervals with a vibrotome (VT1200S, Leica Microsystems, Inc., Bannockbum, IL), and a total of 120–150 tissue sections were sequentially collected into a 24-well plate (e.g., a distance of 960μm in two adjacent sections in each well). every 5th section was reserved for histochemical staining with cresyl violet to analyze neuronal cell death and score brain damage. Stained sections were examined using an Olympus BX-41 upright pathology microscope (Olympus America Inc., Center Valley, PA). The grading scale for neuronal damage in each region was scored as previously described : 0, normal (no apparent neuronal cell death); 1, fewer than 1/3 cells damaged; 2, more than 1/3 but less than 2/3 damaged; and 3, more than 2/3 of cells dead.
Quantification of hemorrhagic volume
Micro-hemorrhages were quantified in cresyl violet-stained serial sections with stereology analysis technique , which utilizes systematic sampling of 25 to 30 serial sections per brain, each section separated by 200 μm along the anteroposterior axis of each brain. Spontaneous ICH after embolic ischemia was examined as described , using a 4x objective lens. Additional validation was carried out by capturing images using a 20x objective and micro-hemorrhage area was measured using the ImageJ analysis software. Care was taken to examine each serial section to include multiple hemorrhage areas per section. Hemorrhage area for each animal was summed and then hemorrhage volumes were calculated by integrating the appropriate area with the section interval thickness (200 μm) and expressed as μm3.
Fluorescence labeling and immunohistochemistry
Cerebral vascular perfusion patterns were examined after embolic cerebral ischemia using high-molecular weight fluorescein-dextran. A modified PE-10 catheter connected to a 1-cc syringe was inserted into the right femoral vein and a solution of FITC-dextran [0.1 mL of 50 mg/mL in PBS; molecular weight (MW) 2,000 KDa, Sigma Chemical Co, St. Louis, MO] was administered for 30 minutes before the animal was sacrificed. Mice were decapitated and the brains were rapidly removed and placed in 4% paraformaldehyde for 24 hours. Coronal sections (100 μm thickness) were cut with a vibrotome and post-fixed in 4% paraformaldehyde. For immunohistochemistry, 40 μm thick brain sections were labeled for microvessel endothelial cells using the specific glycoprotein Lycopersicon esculentum (tomato) lectin conjugated to fluorescein (1:500, FL-1171; Vector Labs, Burlingame, CA) or immunostained with the following antibodies: the endothelial marker rat anti-CD31 (1:50, 550274; BD Biosciences, San Diego, CA); the neuronal markers MAP-2 (1:200, M4403, Clone HM-2; Sigma Chemical Co, St. Louis, MO) and NeuN (1:200, MAB377, Clone A60; Millipore-Chemicon, Temecula, CA), and Fluoro-Jade B (0.0012%, AG310; EMD-Millipore, Temecula, CA) fluorescence staining for degenerating neurons; the ECM basement membrane component laminin (1:200, L9393; Sigma Chemical Co, St. Louis, MO); and the pericyte markers―NG2 (1:200) described , desmin (1:50, M0760, Clone D33; DakoCytomation, Carpinteria, CA), and α-SMA (1:400, MS-113-P1ABX, Clone 1A4; Thermo Scientific-Lab Vision, Fremont, CA); and mouse anti-ZO-1 antibody recognizing BBB tight-junction (1:50, 33–9100; Invitrogen, San Diego, CA). Sections were then visualized with fluorophore-conjugated secondary antibodies (1:200, goat anti-mouse IgG-Alexa488, A11001; goat anti-mouse IgG-Alexa594, A11005; and goat anti-rabbit IgG-Alexa488, A110034; Invitrogen, San Diego, CA).
For double immunostaining, we incubated sections with Pro-Block (PBK125; ScyTek, Logan, UT) for 5 minutes to eliminate the need to match species with the fluorescence-conjugated antibody, followed by incubation with normal goat serum for 2 hours to block nonspecific binding before applying the primary antibody. Specificity controls included omitting the primary or secondary antibody. Sections were counterstained with nuclear DNA dye Hoechst 33342 . Fluorescence images were analyzed with a Leica DMI 6000B fully automated epifluorescence microscope including AF6000 applications for deconvolution (Leica Microsystems Inc., Buffalo Grove, IL) or an Olympus XI-81 spin-disc scanning confocal microscope (Olympus America Inc., Center Valley, PA), and mosaic images were stitched using Montage analysis tools (Slidebook™ from 3I, Denver, CO) for image re-construction.
Measurement of pericytes
We quantified α-SMA-positive pericytes in 4–5 randomized areas in the cortical penumbral region of the lesioned hemisphere and the corresponding areas of the contralateral side by counting approximately 1500 total cells in each hemisphere. We calculated percentages of α-SMA-positive pericytes and both α-SMA/laminin-positive pericytes relative to total cells visualized by the Hoechst dye staining [8, 19, 20] and measured the average lumen diameters of the long- and short-axis of α-SMA labeled pericytes using the ImageJ software. The long diameter (ΦL) is defined as the longest diameter in the lumen circles, while the short diameter (ΦS) is defined as the perpendicular bisector of the long diameter. We compared percentages of laminin-positive pericytes relative to total cells visualized by staining the nuclear DNA of cells with Hoechst dye, and the overall (laminin-positive and -negative) pericyte-encircled lumen diameters.
All experiments were performed in a randomized blinded manner, with data analysis and experiments performed by separate investigators. Each n number represents an individual animal for each experiment. Data were analyzed using Prism 5 software (GraphPad Software, La Jolla, CA) by either paired or unpaired one-tailed Student's t-test for two-group comparisons. All data are presented as means ± SEM. Statistical significance was set at p < 0.05, 0.01 or 0.001, respectively.
This work is dedicated to the memory of co-authors on this report Dr. Fanjun Meng and Ms. Chunyang Zhang, who tragically passed away on July 3rd, 2011. We thank Ms. YingXing Wu for assistance in statistical analysis and Dr. William Stallcup of Sanford-Burnham Medical Research Institute, La Jolla, CA for generously providing the NG2 antibody. This work was supported in part by grants from the American Heart Association (06BGIA0665051Y and 09NSDG2260983) and the Dana Foundation (to ZG), and by NIH grant CA122417 (to SM and MC).
- Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, et al: Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation. 2011, 123 (4): e18-e209. 10.1161/CIR.0b013e3182009701.PubMed CentralView ArticlePubMedGoogle Scholar
- Lo EH: A new penumbra: transitioning from injury into repair after stroke. Nature Medicine. 2008, 14 (5): 497-500. 10.1038/nm1735.View ArticlePubMedGoogle Scholar
- Moskowitz MA, Lo EH, Iadecola C: The science of stroke: mechanisms in search of treatments. Neuron. 2010, 67 (2): 181-198. 10.1016/j.neuron.2010.07.002.PubMed CentralView ArticlePubMedGoogle Scholar
- Gu Z, Cui J, Lipton SA: Matrix Metalloproteinases in Cerebral Hypoxia-Ischemia. Matrix metalloproteinases in cerebral hypoxia-ischemia. Edited by: Haddad Gabriel G, Shan Ping Yu. 2009, San Diego: Humana Press, 225-238.Google Scholar
- Rosenberg GA: Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009, 8 (2): 205-216. 10.1016/S1474-4422(09)70016-X.View ArticlePubMedGoogle Scholar
- del Zoppo GJ: Acute stroke–on the threshold of a therapy?. N Engl J Med. 1995, 333 (24): 1632-1633. 10.1056/NEJM199512143332410.View ArticlePubMedGoogle Scholar
- Yong VW: Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci. 2005, 6 (12): 931-944. 10.1038/nrn1807.View ArticlePubMedGoogle Scholar
- Lam CK, Yoo T, Hiner B, Liu Z, Grutzendler J: Embolus extravasation is an alternative mechanism for cerebral microvascular recanalization. Nature. 2010, 465 (7297): 478-482. 10.1038/nature09001.PubMed CentralView ArticlePubMedGoogle Scholar
- Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S: Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke. 2003, 34 (9): 2165-2170. 10.1161/01.STR.0000088062.86084.F2.View ArticlePubMedGoogle Scholar
- Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleira S, Arenillas J, Monasterio J: Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke. 2001, 32 (12): 2762-2767. 10.1161/hs1201.99512.View ArticlePubMedGoogle Scholar
- Switzer JA, Hess DC, Ergul A, Waller JL, Machado LS, Portik-Dobos V, Pettigrew LC, Clark WM, Fagan SC: Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke. 2011, 42 (9): 2633-2635. 10.1161/STROKEAHA.111.618215.PubMed CentralView ArticlePubMedGoogle Scholar
- Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, Davalos A: Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke. 2003, 34 (1): 40-46. 10.1161/01.STR.0000046764.57344.31.View ArticlePubMedGoogle Scholar
- Gasche Y, Fujimura M, Morita-Fujimura Y, Copin JC, Kawase M, Massengale J, Chan PH: Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood–brain barrier dysfunction. J Cereb Blood Flow Metab. 1999, 19 (9): 1020-1028.View ArticlePubMedGoogle Scholar
- Lapchak PA, Chapman DF, Zivin JA: Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000, 31 (12): 3034-3040. 10.1161/01.STR.31.12.3034.View ArticlePubMedGoogle Scholar
- Wang J, Tsirka SE: Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain. 2005, 128 (Pt 7): 1622-1633.View ArticlePubMedGoogle Scholar
- Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, Smith JW, Liddington RC, Lipton SA: S-Nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science. 2002, 297 (5584): 1186-1190. 10.1126/science.1073634.View ArticlePubMedGoogle Scholar
- Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, Fini ME, Lo EH: Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood–brain barrier and white matter components after cerebral ischemia. J Neurosci. 2001, 21 (19): 7724-7732.PubMedGoogle Scholar
- Armulik A, Genove G, Mae M, Nisancioglu MH, Wallgard E, Niaudet C, He L, Norlin J, Lindblom P, Strittmatter K, et al: Pericytes regulate the blood–brain barrier. Nature. 2010, 468 (7323): 557-561. 10.1038/nature09522.View ArticlePubMedGoogle Scholar
- Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV: Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010, 68 (3): 409-427. 10.1016/j.neuron.2010.09.043.PubMed CentralView ArticlePubMedGoogle Scholar
- Yemisci M, Gursoy-Ozdemir Y, Vural A, Can A, Topalkara K, Dalkara T: Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat Med. 2009, 15 (9): 1031-1037. 10.1038/nm.2022.View ArticlePubMedGoogle Scholar
- Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, Wang X, Lo EH: Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. 2006, 12 (4): 441-445. 10.1038/nm1387.View ArticlePubMedGoogle Scholar
- Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Okulski P, Dzwonek J, Costa RM, Silva AJ, Kaczmarek L, Huntley GW: Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci. 2006, 26 (7): 1923-1934. 10.1523/JNEUROSCI.4359-05.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Yong VW, Agrawal SM, Stirling DP: Targeting MMPs in acute and chronic neurological conditions. Neurotherapeutics. 2007, 4 (4): 580-589. 10.1016/j.nurt.2007.07.005.View ArticlePubMedGoogle Scholar
- Jin DK, Shido K, Kopp H-G, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B, et al: Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med. 2006, 12 (5): 557-567. 10.1038/nm1400.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang H, Trivedi A, Lee J-U, Lohela M, Lee SM, Fandel TM, Werb Z, Noble-Haeusslein LJ: Matrix metalloproteinase-9 and stromal cell-derived factor-1 act synergistically to support migration of blood-borne monocytes into the injured spinal cord. J Neurosci. 2011, 31 (44): 15894-15903. 10.1523/JNEUROSCI.3943-11.2011.PubMed CentralView ArticlePubMedGoogle Scholar
- Meighan SE, Meighan PC, Choudhury P, Davis CJ, Olson ML, Zornes PA, Wright JW, Harding JW: Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. J Neurochem. 2006, 96 (5): 1227-1241. 10.1111/j.1471-4159.2005.03565.x.View ArticlePubMedGoogle Scholar
- Lipton SA: Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci. 2007, 8 (10): 803-808.View ArticlePubMedGoogle Scholar
- Brown S, Bernardo MM, Li ZH, Kotra LP, Tanaka Y, Fridman R, Mobashery S: Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc. 2000, 122: 6799-6800. 10.1021/ja001461n.View ArticleGoogle Scholar
- Gu Z, Cui J, Brown S, Fridman R, Mobashery S, Strongin AY, Lipton SA: A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci. 2005, 25 (27): 6401-6408. 10.1523/JNEUROSCI.1563-05.2005.View ArticlePubMedGoogle Scholar
- Yu F, Kamada H, Niizuma K, Endo H, Chan PH: Induction of mmp-9 expression and endothelial injury by oxidative stress after spinal cord injury. J Neurotrauma. 2008, 25 (3): 184-195. 10.1089/neu.2007.0438.PubMed CentralView ArticlePubMedGoogle Scholar
- Guo Z, Sun X, He Z, Jiang Y, Zhang X, Zhang JH: Matrix metalloproteinase-9 potentiates early brain injury after subarachnoid hemorrhage. Neurol Res. 2010, 32 (7): 715-720. 10.1179/016164109X12478302362491.View ArticlePubMedGoogle Scholar
- Liu J, Jin X, Liu KJ, Liu W: Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood–brain barrier damage in early ischemic stroke stage. J Neurosci. 2012, 32 (9): 3044-3057. 10.1523/JNEUROSCI.6409-11.2012.PubMed CentralView ArticlePubMedGoogle Scholar
- He ZJ, Huang ZT, Chen XT, Zou ZJ: Effects of matrix metalloproteinase 9 inhibition on the blood brain barrier and inflammation in rats following cardiopulmonary resuscitation. Chin Med J (Engl). 2009, 122 (19): 2346-2351.Google Scholar
- Zhang Z, Chopp M, Zhang RL, Goussev A: A mouse model of embolic focal cerebral ischemia. J Cereb Blood Flow Metab. 1997, 17 (10): 1081-1088.View ArticlePubMedGoogle Scholar
- Cui JK, Hsu CY, Liu PK: Suppression of postischemic hippocampal nerve growth factor expression by a c-fos antisense oligodeoxynucleotide. J Neurosci. 1999, 19 (4): 1335-1344.PubMedGoogle Scholar
- Helton R, Cui J, Scheel JR, Ellison JA, Ames C, Gibson C, Blouw B, Ouyang L, Dragatsis I, Zeitlin S, et al: Brain-specific knock-out of hypoxia-inducible factor-1alpha reduces rather than increases hypoxic-ischemic damage. J Neurosci. 2005, 25 (16): 4099-4107. 10.1523/JNEUROSCI.4555-04.2005.View ArticlePubMedGoogle Scholar
- Chen J, Zacharek A, Zhang C, Jiang H, Li Y, Roberts C, Lu M, Kapke A, Chopp M: Endothelial Nitric Oxide Synthase Regulates Brain-Derived Neurotrophic Factor Expression and Neurogenesis after Stroke in Mice. J Neurosci. 2005, 25 (9): 2366-2375. 10.1523/JNEUROSCI.5071-04.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang X, Tsuji K, Lee S-R, Ning M, Furie KL, Buchan AM, Lo EH: Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke. 2004, 35 (11 Suppl 1): 2726-2730.View ArticlePubMedGoogle Scholar
- Garden GA, Budd SL, Tsai E, Hanson L, Kaul M, D'Emilia DM, Friedlander RM, Yuan J, Masliah E, Lipton SA: Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci. 2002, 22 (10): 4015-4024.PubMedGoogle Scholar
- Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH: Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009, 40 (6): 2244-2250. 10.1161/STROKEAHA.108.541128.PubMed CentralView ArticlePubMedGoogle Scholar
- Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH: Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke. 2008, 39 (12): 3372-3377. 10.1161/STROKEAHA.108.514026.PubMed CentralView ArticlePubMedGoogle Scholar
- Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z: MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 1998, 93 (3): 411-422. 10.1016/S0092-8674(00)81169-1.PubMed CentralView ArticlePubMedGoogle Scholar
- Leker RR, Soldner F, Velasco I, Gavin DK, Androutsellis-Theotokis A, McKay RD: Long-lasting regeneration after ischemia in the cerebral cortex. Stroke. 2007, 38 (1): 153-161. 10.1161/STROKEAHA.107.496919.View ArticlePubMedGoogle Scholar
- van Meer MP, van der Marel K, Wang K, Otte WM, El Bouazati S, Roeling TA, Viergever MA, van der Sprenkel JW Berkelbach, Dijkhuizen RM: Recovery of sensorimotor function after experimental stroke correlates with restoration of resting-state interhemispheric functional connectivity. J Neurosci. 2010, 30 (11): 3964-3972. 10.1523/JNEUROSCI.5709-09.2010.View ArticlePubMedGoogle Scholar
- Forbes C, Shi Q, Fisher JF, Lee M, Hesek D, Llarrull LI, Toth M, Gossing M, Fridman R, Mobashery S: Active Site Ring-Opening of a Thiirane Moiety and Picomolar Inhibition of Gelatinases. Chem Biol Drug Des. 2009, 74 (6): 527-534. 10.1111/j.1747-0285.2009.00881.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu H, Shubayev V: Matrix metalloproteinase-9 controls proliferation of NG2+ progenitor cells immediately after spinal cord injury. Exp Neurol. 2011, 231 (2): 236-246. 10.1016/j.expneurol.2011.06.015.PubMed CentralView ArticlePubMedGoogle Scholar
- Lee M, Bernardo MM, Meroueh SO, Brown S, Fridman R, Mobashery S: Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors. Org Lett. 2005, 7 (20): 4463-4465. 10.1021/ol0517269.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.